Vericel Corp (VCEL): Operating Cash Flow
$51.91M
Year ended 2025-12-31
$69.67M
Trailing 12 months to 2026-06-30
+43.2%
3-year compound annual growth
+24.2%
5-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $51.91M | -10.8% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $58.16M | +64.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $35.31M | +99.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $17.69M | -39.1% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $29.04M | +65.3% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $17.57M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$7.18M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$412.0K | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | -$13.18M | n/m | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | -$19.89M | n/m | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | -$13.35M | n/m | 2018-03-05, From 2015-01-01 |
| 2014-12-31 | -$25.41M | n/m | 2017-03-13, From 2014-01-01 |
| 2013-12-31 | -$19.94M | n/m | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | -$29.55M | n/m | 2015-03-25, From 2012-01-01 |
| 2011-12-31 | -$24.49M | n/a | 2014-03-13, From 2011-01-01 |
| No annual figure between 2010-06-30 and 2011-12-31. | |||
| 2010-06-30 | -$15.09M | n/m | 2013-03-18, From 2009-07-01 |
| 2009-06-30 | -$13.80M | n/a | 2012-03-15, From 2008-07-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Vericel Corp (VCEL) | 2025-12-31 | $51.91M | -10.8% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$45.99M | n/m |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | -$302.41M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $7.71M | n/m |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$47.63M | n/m |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $200.87M | +62.7% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$10.71M | n/m |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | -$73.21M | n/m |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | -$123.96M | n/m |
Compare VCEL, ADPT, IOVA, VXRT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗